Although surgical and angiointervention techniques remain the cornerstone for the management of severe bleeding after trauma, adjunct therapeutic strategies such as local or systemic hemostatic agents can play an important role. This article reviews the role and efficacy of the available hemostatic agents.
Get full access to this article
View all access options for this article.
References
1.
TeixeiraP.G.InabaK.HadjizachariaP.Preventable or potentially preventable mortality at a mature trauma center.J Trauma2007; 63: 1338–46; discussion 1346–7.
2.
TienH.C.SpencerF.TremblayL.N.Preventable deaths from hemorrhage at a Level I Canadian trauma center.J Trauma2007; 62: 142–6.
3.
RecinosG.InabaK.DuboseJ.Local and systemic hemostatics in trauma: a review.Ulus Travma Acil Cerrahi Derg2008; 14: 175–81.
4.
RheeP.InabaK.Coagulopathy in the trauma patient. In: CameronJ.L.M.D.., ed. Current Surgical Therapy.9th ed.Philadelphia, PA: Mosby Elsevier; 2008: 940–4.
5.
KrízováP.MásováL.SuttnarJ.The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose.J Biomed Mater Res A2007; 82: 274–80.
6.
BrodbeltA.R.MilesJ.B.FoyP.M.BroomeJ.C.Intraspinal oxidised cellulose (Surgicel) causing delayed paraplegia after thoracotomy—a report of three cases.Ann R Coll Surg Engl2002; 84: 97–9.
7.
SpanglerD.RothenburgerS.NguyenK.In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms.Surg Infect (Larchmt)2003; 4: 255–62.
8.
BjorensonJ.E.GroveH.F.ListM.G.Sr.Effects of hemostatic agents on the pH of body fluids.J Endod1986; 12: 289–92.
9.
MatthewT.L.SpotnitzW.D.KronI.L.Four years’ experience with fibrin sealant in thoracic and cardiovascular surgery.Ann Thorac Surg1990; 50: 40–3; discussion 43–4.
10.
CodispotiM.MankadP.S.Significant merits of a fibrin sealant in the presence of coagulopathy following paediatric cardiac surgery: randomised controlled trial.Eur J Cardiothorac Surg2002; 22: 200–5.
11.
HolcombJ.B.PusateriA.E.HarrisR.A.Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries.J Trauma1999; 47: 233–40; discussion 240–2.
12.
FeinsteinA.J.VarelaJ.E.CohnS.M.Fibrin glue eliminates the need for packing after complex liver injuries.Yale J Biol Med2001; 74: 315–21.
13.
KramH.B.NathanR.C.StaffordF.J.Fibrin glue achieves hemostasis in patients with coagulation disorders.Arch Surg1989; 124: 385–7.
14.
ChenR.J.FangJ.F.LinB.C.Selective application of laparoscopy and fibrin glue in the failure of nonoperative management of blunt hepatic trauma.J Trauma1998; 44: 691–5.
15.
MartinowitzU.SchulmanS.HoroszowskiH.HeimM.Role of fibrin sealants in surgical procedures on patients with hemostatic disorders.Clin Orthop Relat Res1996; 65–75.
16.
MartinowitzU.VaronD.HeimM.The role of fibrin tissue adhesives in surgery of haemophilia patients.Haemophilia1998; 4: 443–8.
17.
KavakliK.Fibrin glue and clinical impact on haemophilia care.Haemophilia1999; 5: 392–6.
18.
CanonicoS.SciaudoneG.PacificoF.SantorielloA.Inguinal hernia repair in patients with coagulation problems: prevention of postoperative bleeding with human fibrin glue.Surgery1999; 125: 315–7.
19.
IsmailS.CombsM.J.GoodmanN.C.Reduction of femoral arterial bleeding post catheterization using percutaneous application of fibrin sealant.Cathet Cardiovasc Diagn1995; 34: 88–95.
20.
AlamH.B.UyG.B.MillerD.Comparative analysis of hemostatic agents in a swine model of lethal groin injury.J Trauma2003; 54: 1077–82.
21.
WrightF.L.HuaH.T.VelmahosG.Intracorporeal use of the hemostatic agent QuickClot in a coagulopathic patient with combined thoracoabdominal penetrating trauma.J Trauma2004; 56: 205–8.
22.
AlamH.B.ChenZ.JaskilleA.Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swine.J Trauma2004; 56: 974–83.
23.
PusateriA.E.DelgadoA.V.DickE.J.Jr.MartinezR.S.HolcombJ.B.RyanK.L.Application of a granular mineral-based hemostatic agent (QuikClot) to reduce blood loss after grade V liver injury in swine.J Trauma2004; 57: 555–62; discussion 562.
24.
WrightJ.K.KalnsJ.WolfE.A.Thermal injury resulting from application of a granular mineral hemostatic agent.J Trauma2004; 57: 224–30.
25.
EryilmazM.OzerT.MentexsO.Is the zeolite hemostatic agent beneficial in reducing blood loss during arterial injury?Ulus Travma Acil Cerrahi Derg2009; 15: 7–11.
26.
MahajnaA.HirshM.KrauszM.M.Use of the hemostatic agent QuikClot for the treatment of massive splenic injury in a rat model.Eur Surg Res2007; 39: 251–7.
27.
ArnaudF.TomoriT.SaitoR.Comparative efficacy of granular and bagged formulations of the hemostatic agent QuikClot.J Trauma2007; 63: 775–82.
28.
RheeP.BrownC.MartinM.QuikClot use in trauma for hemorrhage control: case series of 103 documented uses.J Trauma2008; 64: 1093–9.
29.
InabaK.RheeP.TeixeiraP.G.Intracorporeal use of advanced local hemostatics in a damage control swine model of grade IV liver injury.J Trauma2011; 71: 1312–8.
ChouT.C.FuE.WuC.J.YehJ.H.Chitosan enhances platelet adhesion and aggregation.Biochem Biophys Res Commun2003; 302: 480–3.
32.
ThatteH.S.ZagarinsS.E.AmijiM.KhuriS.F.Poly-Nacetyl glucosamine-mediated red blood cell interactions.J Trauma2004; 57(suppl): S7–12.
33.
SchwaitzbergS.D.ChanM.W.ColeD.J.Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage.J Trauma2004; 57(suppl): S29–32.
34.
KlokkevoldP.R.FukayamaH.SungE.C.BertolamiC.N.The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits.J Oral Maxillofac Surg1999; 57: 49–52.
35.
ChaoH.H.TorchianaD.F.BioGlue: albumin/glutaraldehyde sealant in cardiac surgery.J Card Surg2003; 18: 500–3.
36.
CoselliJ.S.BavariaJ.E.FehrenbacherJ.Prospective randomized study of a protein-based tissue adhesive used as a hemostatic and structural adjunct in cardiac and vascular anastomotic repair procedures.J Am Coll Surg2003; 197: 243–52; discussion 252–3.
37.
GundryS.R.BlackK.IzutaniH.Sutureless coronary artery bypass with biologic glued anastomoses: preliminary in vivo and in vitro results.J Thorac Cardiovasc Surg2000; 120: 473–7.
FürstW.BanerjeeA.Release of glutaraldehyde from an albumin-glutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity.Ann Thorac Surg2005; 79: 1522–8; discussion 1529.
40.
ZehnderJ.L.LeungL.L.Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.Blood1990; 76: 2011–6.
41.
BänningerH.HardeggerT.ToblerA.Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.Br J Haematol1993; 85: 528–32.
42.
FisherW.E.ChaiC.HodgesS.E.Effect of BioGlue(R) on the incidence of pancreatic fistula following pancreas resection.J Gastrointest Surg2008; 12: 882–90.
43.
VournakisJ.N.DemchevaM.WhitsonA.Isolation, purification, and characterization of poly-N-acetyl glucosamine use as a hemostatic agent.J Trauma2004; 57(suppl 1): S2–6.
44.
FischerT.H.ValeriC.R.SmithC.J.Non-classical processes in surface hemostasis: mechanisms for the poly-N-acetyl glucosamine induced alteration of red blood cell morphology and surface prothrombogenicity.Biomed Mater2008; 3: 1–9.
45.
FischerT.H.ThatteH.S.NicholsT.C.Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis.Biomaterials2005; 26: 5433–43.
46.
ValeriC.R.SreyR.TilahunD.RagnoG.In vitro effects of poly-N-acetyl glucosamine on the activation of platelets in platelet-rich plasma with and without red blood cells.J Trauma2004; 57(suppl 1): S22–5.
47.
IkedaY.YoungL.H.VournakisJ.N.LeferA.M.Vascular effects of poly-N-acetyl glucosamine in isolated rat aortic rings.J Surg Res2002; 102: 215–20.
48.
JewelewiczD.D.CohnS.M.CrookesB.A.ProctorK.G.Modified rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury.J Trauma2003; 55: 275–80.
49.
ChanM.W.SchwaitzbergS.D.DemchevaM.Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage.J Trauma2000; 48: 454–7; discussion 457–8.
50.
VournakisJ.N.DemchevaM.WhitsonA.B.The RDH bandage: hemostasis and survival in a lethal aortotomy hemorrhage model.J Surg Res2003; 113: 1–5.
51.
SchwaitzbergS.D.ChanM.W.ColeD.J.Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage.J Trauma2004; 57(suppl): S29–32.
52.
RaymondJ.Connolly, Application of the poly-N-acetyl glucosamine-derived rapid deployment hemostat trauma dressing in severe/lethal swine hemorrhage trauma models.J Trauma2004; 57(suppl): S26–8.
53.
KingD.R.de MoyaM.M.McKenneyM.G.CohnS.M.Modified rapid deployment hemostat terminates bleeding from hepatic rupture in third trimester.J Trauma2006; 61: 739–42.
54.
KingD.R.CohnS.M.ProctorK.G.; Miami Clinical Trials Group. Modified rapid deployment hemostat bandage terminates bleeding in coagulopathic patients with severe visceral injuries.J Trauma2004; 57: 756–9.
55.
KingD.R.SchreiberM.A.The mRDH bandage provides effective hemostasis in trauma and surgical hemorrhage.J Trauma2011; 71(suppl 1): S167–70.
56.
KingD.CohnS.M.SchreiberM.A modified rapid deployment hemostat bandage surgeon experience at Level 1 trauma centers.General Surgery News2010; 37: 2.
57.
JeroukhimovI.JewelewiczD.ZaiasJ.Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury.J Trauma2002; 53: 1053–7.
58.
LynnM.JerokhimovI.JewelewiczD.Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study.J Trauma2002; 52: 703–7.
59.
KenetG.WaldenR.EldadA.MartinowitzU.Treatment of traumatic bleeding with recombinant factor VI.Lancet1999; 354: 1879.
60.
ShapiroA.D.GilchristG.S.HootsW.K.Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.Thromb Haemost1998; 80: 773–8.
61.
SchreiberM.A.HolcombJ.B.HednerU.The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.J Trauma2002; 53: 252–7; discussion 257–9.
62.
LeviM.PetersM.BüllerH.R.Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.Crit Care Med2005; 33: 883–90.
63.
MartinowitzU.KenetG.SegalE.Recombinant activated factor VII for adjunctive hemorrhage control in trauma.J Trauma2001; 51: 431–8; discussion 438–9.
64.
DuttonR.P.HessJ.R.ScaleaT.M.Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients.J Clin Anesth2003; 15: 184–8.
65.
EikelboomJ.W.BirdR.BlytheD.Recombinant activated factor VII for the treatment of life-threatening haemorrhage.Blood Coagul Fibrinolysis2003; 14: 713–7.
66.
MartinowitzU.KenetG.LubetskiA.Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.Can J Anaesth2002; 49: S15–20.
67.
BoffardK.D.RiouB.WarrenB.Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.J Trauma2005; 59: 8–15; discussion 15–8.
68.
RizoliS.B.BoffardK.D.RiouB.Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.Crit Care2006; 10: R178.
69.
LeviM.LevyJ.H.AndersenH.F.TruloffD.Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med2010; 363: 1791–800; erratum in N Engl J Med 2011; 365: 1944.
70.
HauserC.J.BoffardK.DuttonR.Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.; CONTROL Study Group.J Trauma2010; 69: 489–500.
71.
Williams-JohnsonJ.A.McDonaldA.H.StrachanG.G.WilliamsE.W.Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.Lancet2010; 376: 23–32.
72.
GuerrieroC.CairnsJ.PerelP.CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.PLoS One2011; 6: e18987.
73.
MorrisonJ.J.DuboseJ.J.RasmussenT.E.MidwinterM.J.Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) Study.Arch Surg2011 Oct 17 [Epub ahead of print].
